We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
26
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.4M 1.14%
261,365
-225,883
-46% -$6.67M
PRAX icon
27
Praxis Precision Medicines
PRAX
$8.58B
$10.3M 1.13%
168,388
-31,612
-16% -$1.42M
CYTK icon
28
Cytokinetics
CYTK
$10.9B
$10.2M 1.12%
145,147
+115,147
+384% +$8.91M
ANNX icon
29
Annexon
ANNX
$863M
$10.1M 1.1%
1,405,000
-1,245,000
-47% -$6.46M
ARE icon
30
PUT
Alexandria Real Estate Equities
ARE
$9.15B
$9.45M 1.04%
73,300
– –
INSM icon
31
CALL
Insmed
INSM
$22B
$9.42M 1.03%
347,200
+347,000
+173,500% +$9.71M
IMVT icon
32
Immunovant
IMVT
$8.11B
$8.95M 0.98%
276,925
+43,531
+19% +$1.59M
BBIO icon
33
BridgeBio Pharma
BBIO
$16.1B
$8.72M 0.96%
282,013
-191,113
-40% -$6.5M
CPRX
34
DELISTED
Catalyst Pharmaceutical
CPRX
$8.26M 0.91%
518,386
+12,524
+2% +$189K
FDMT icon
35
CALL
4D Molecular Therapeutics
FDMT
$526M
$8.21M 0.9%
+257,600
New +$6.57M
FDMT icon
36
PUT
4D Molecular Therapeutics
FDMT
$526M
$8.21M 0.9%
+257,600
New +$6.57M
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$351M
$8M 0.88%
297,096
+57,370
+24% +$1.63M
MLTX icon
38
PUT
MoonLake Immunotherapeutics
MLTX
$1.62B
$7.94M 0.87%
158,000
-42,600
-21% -$2.31M
MGNX icon
39
CALL
MacroGenics
MGNX
$240M
$7.71M 0.84%
+523,500
New +$7.91M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$27.4B
$7.7M 0.84%
+51,541
New +$8.6M
NUVL
41
DELISTED
Nuvalent
NUVL
$7.63M 0.84%
101,601
-156,541
-61% -$12.5M
PYXS icon
42
Pyxis Oncology
PYXS
$182M
$7.08M 0.78%
+1,662,408
New +$6.99M
CORT icon
43
CALL
Corcept Therapeutics
CORT
$12.7B
$7.04M 0.77%
279,500
+8,200
+3% +$194K
CYTK icon
44
PUT
Cytokinetics
CYTK
$10.9B
$7.01M 0.77%
100,000
+96,500
+2,757% +$7.46M
LYRA
45
DELISTED
LYRA THERAPEUTICS INC
LYRA
$6.57M 0.72%
21,137
-3,951
-16% -$1.05M
ABEO icon
46
Abeona Therapeutics
ABEO
$369M
$6.44M 0.71%
888,593
+288,593
+48% +$1.83M
SRRK icon
47
CALL
Scholar Rock
SRRK
$5.87B
$6.43M 0.71%
+362,300
New +$5.7M
VRNA
48
DELISTED
Verona Pharma
VRNA
$6.04M 0.66%
375,310
+7,842
+2% +$136K
APLS
49
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$5.88M 0.64%
+100,000
New +$6.37M
ARQT icon
50
Arcutis Biotherapeutics
ARQT
$3.5B
$5.84M 0.64%
+589,642
New +$4.4M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.